Advertisement

Topics

Olaparib Extends PFS in Relapsed Ovarian Cancer, With Good QOL

20:23 EDT 7 Aug 2017 | Cancer Networks

Olaparib tablet maintenance therapy provided a significant improvement in progression-free survival over placebo in patients with relapsed, platinum-sensitive ovarian cancer with a BRCA1/2 mutation.

Original Article: Olaparib Extends PFS in Relapsed Ovarian Cancer, With Good QOL

NEXT ARTICLE

More From BioPortfolio on "Olaparib Extends PFS in Relapsed Ovarian Cancer, With Good QOL"

Quick Search
Advertisement
 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...